Demand for CMO fermentation capacity has exploded in the past couple of years, and it’s become very important that we find new ways to meet industry demand. That’s a big reason we’re seeing single-use fermentation (SUF) technology as an accelerating trend in the industry, especially for us at Aldevron.
Last month I took part in a workshop on gene and cell therapy manufacturing at the Alliance for Regenerative Medicine’s Cell and Gene Meeting on the Mesa. It was a pleasure to participate with very distinguished colleagues: Matthew Caple, Vice President of Site Operations at Brammer Bio; Mike Kelly, Director, Asset Leadership and Portfolio Management, Gene Therapy, Biogen; and Michael Roberts, Ph.D., Chief Scientific Officer, Synpromics.
The workshop was moderated by Jessica Carmen, Ph.D., Director of Business Development, Cellular Therapy Partnerships, MaxCyte and sponsored by MaxCyte and Brammer Bio. Dr. Carmen did a great job taking us on a journey through manufacturing from construct design through raw material manufacturing, viral vector manufacturing, and ultimately commercialization.
"Biomanufacturing" and "efficiency" are two terms that are not commonly seen together, but researchers at the University of Wisconsin-Madison Engineering Department along with protein manufacturing experts here at Aldevron are taking big steps to change that.
The application of Quick Response Manufacturing (QRM) theory to biological processes is a unique initiative whose goal of reducing lead times for manufacturing operations is the core focus of the UW and Aldevron partnership.
Last month, I participated in a panel discussion at the Rejuvenation Biotechnology 2016 Conference sponsored by the SENS Research Foundation at the Buck Institute for Research on Aging in Novato, California. The title of our panel was "As Paths To Clinic Are Expedited, The Distinction Between Development And Manufacturing Is Becoming Increasingly Blurred".
One of the panelists was Alan Moore, Vice President and Commercial Chief for Biologics and Advanced Therapies of Wuxi AppTec. Alan and I have known each other for some time and it was great to reconnect with him. His presentation covered the impressive work that Wuxi has done in autologous cell processing.